Expression of PAR-4 and PHLDA1 is prognostic for overall and disease-free survival in oral squamous cell carcinomas

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorCOUTINHO-CAMILLO, Claudia Malheiros
dc.contributor.authorLOURENCO, Silvia Vanessa
dc.contributor.authorNONOGAKI, Suely
dc.contributor.authorVARTANIAN, Jose Guilherme
dc.contributor.authorNAGAI, Maria Aparecida
dc.contributor.authorKOWALSKI, Luiz Paulo
dc.contributor.authorSOARES, Fernando Augusto
dc.date.accessioned2013-09-23T16:37:37Z
dc.date.available2013-09-23T16:37:37Z
dc.date.issued2013
dc.description.abstractPAR-4 is a tumor suppressor protein with a pro-apoptotic function and down-regulation of PAR-4 is seen in a variety of tumors. PHLDA1 gene overexpression has been shown to reduce cell proliferation and induce cell death in a variety of cell types. In this study, 229 cases of oral squamous cell carcinoma (OSCC), arranged in a tissue microarray, were analyzed by immunohistochemistry. PAR-4 expression was predominantly moderate to strong and expression of PHLDA1 was predominantly negative or weak. Cytoplasmic expression of PAR-4 was associated with advanced clinical stage. Expression of PHLDA1 was associated with advanced clinical stage of the tumour. Five-year overall and disease-free survival rates differed significantly between cases that did and cases that did not express PHLDA1, and by multivariate analysis, expression of PHLDA1 and PAR-4 were independent prognostic factors in OSCC patients. Expression of PAR-4 and PHLDA1 is altered in OSCC and might be a valuable prognostic indicator for this disease.
dc.description.indexMEDLINE
dc.description.sponsorshipFAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo) [98/14335-2, 07/50608-4, 08/57887-9]
dc.identifier.citationVIRCHOWS ARCHIV, v.463, n.1, p.31-39, 2013
dc.identifier.doi10.1007/s00428-013-1438-9
dc.identifier.issn0945-6317
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1902
dc.language.isoeng
dc.publisherSPRINGER
dc.relation.ispartofVirchows Archiv
dc.rightsrestrictedAccess
dc.rights.holderCopyright SPRINGER
dc.subjectOral squamous cell carcinoma
dc.subjectTissue microarray
dc.subjectImmunohistochemistry
dc.subjectPAR-4
dc.subjectPHLDA1
dc.subject.othertumor-suppressor par-4
dc.subject.otherdown-regulation
dc.subject.otherbreast-cancer
dc.subject.otherapoptosis
dc.subject.othertdag51
dc.subject.othergene
dc.subject.othercontributes
dc.subject.othergrowth
dc.subject.otherdeath
dc.subject.otheractivation
dc.subject.wosPathology
dc.titleExpression of PAR-4 and PHLDA1 is prognostic for overall and disease-free survival in oral squamous cell carcinomas
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalCOUTINHO-CAMILLO, Claudia Malheiros:AC Camargo Canc Ctr, Dept Anat Pathol, Sao Paulo, Brazil; Ctr Int Pesquisa, AC Camargo Canc Ctr, BR-01508010 Sao Paulo, Brazil
hcfmusp.author.externalLOURENCO, Silvia Vanessa:Univ Sao Paulo, Sch Dent, Dept Gen Pathol, Sao Paulo, Brazil
hcfmusp.author.externalNONOGAKI, Suely:AC Camargo Canc Ctr, Dept Anat Pathol, Sao Paulo, Brazil
hcfmusp.author.externalVARTANIAN, Jose Guilherme:Hosp AC Camargo Fund Antonio Prudente, Dept Otorhinolaryngol & Head & Neck Surg, Sao Paulo, Brazil
hcfmusp.author.externalKOWALSKI, Luiz Paulo:Hosp AC Camargo Fund Antonio Prudente, Dept Otorhinolaryngol & Head & Neck Surg, Sao Paulo, Brazil
hcfmusp.author.externalSOARES, Fernando Augusto:AC Camargo Canc Ctr, Dept Anat Pathol, Sao Paulo, Brazil; Univ Sao Paulo, Sch Dent, Dept Gen Pathol, Sao Paulo, Brazil
hcfmusp.citation.scopus18
hcfmusp.contributor.author-fmusphcMARIA APARECIDA NAGAI
hcfmusp.description.beginpage31
hcfmusp.description.endpage39
hcfmusp.description.issue1
hcfmusp.description.volume463
hcfmusp.origemWOS
hcfmusp.origem.pubmed23748915
hcfmusp.origem.scopus2-s2.0-84879840135
hcfmusp.origem.wosWOS:000321066900005
hcfmusp.publisher.cityNEW YORK
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceBoehrer S, HEMATOL J, V2, P103
hcfmusp.relation.referenceBurikhanov R, 2009, CELL, V138, P377, DOI 10.1016/j.cell.2009.05.022
hcfmusp.relation.referenceChaudhry P, 2012, MOL CELL BIOL, V32, P826, DOI 10.1128/MCB.06321-11
hcfmusp.relation.referenceCook J, 1999, ONCOGENE, V18, P1205, DOI 10.1038/sj.onc.1202416
hcfmusp.relation.referenceCoutinho-Camillo CM, 2010, HISTOPATHOLOGY, V57, P304, DOI 10.1111/j.1365-2559.2010.03621.x
hcfmusp.relation.referenceCoutinho-Camillo CM, 2011, HEAD NECK-J SCI SPEC, V33, P1191, DOI 10.1002/hed.21602
hcfmusp.relation.referenceFrank D, 1999, MAMM GENOME, V10, P1150, DOI 10.1007/s003359901182
hcfmusp.relation.referenceGomes I, 1999, J NEUROCHEM, V73, P612, DOI 10.1046/j.1471-4159.1999.0730612.x
hcfmusp.relation.referenceGoswami A, 2006, CANCER RES, V66, P2889, DOI 10.1158/0008-5472.CAN-05-4458
hcfmusp.relation.referenceHanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
hcfmusp.relation.referenceHanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
hcfmusp.relation.referenceHossain GS, 2003, J BIOL CHEM, V278, P30317, DOI 10.1074/jbc.M212897200
hcfmusp.relation.referenceJohnson EO, 2011, J CELL SCI, V124, P2711, DOI 10.1242/jcs.084970
hcfmusp.relation.referenceKogel D, 2001, BRIT J CANCER, V85, P1801, DOI 10.1054/bjoc.2001.2158
hcfmusp.relation.referenceLee JW, 2010, HEAD NECK-J SCI SPEC, V32, P877, DOI 10.1002/hed.21282
hcfmusp.relation.referenceMassano J, 2006, ORAL SURG ORAL MED O, V102, P67, DOI 10.1016/j.tripleo.2005.07.038
hcfmusp.relation.referenceMoreno-Bueno G, 2007, CANCER RES, V67, P1927, DOI 10.1158/0008-5472.CAN-06-2687
hcfmusp.relation.referenceNagai MA, 2010, INT J ONCOL, V37, P41, DOI 10.3892/ijo_00000651
hcfmusp.relation.referenceNagai MA, 2007, BREAST CANCER RES TR, V106, P49, DOI 10.1007/s10549-006-9475-6
hcfmusp.relation.referenceNeef R, 2002, CANCER RES, V62, P5920
hcfmusp.relation.referenceOberg HH, 2004, CELL DEATH DIFFER, V11, P674, DOI 10.1038/sj.cdd.4401407
hcfmusp.relation.referenceOberst MD, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-189
hcfmusp.relation.referenceOhyama M, 2006, J CLIN INVEST, V116, P249, DOI 10.1172/JCI26043
hcfmusp.relation.referencePark CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7
hcfmusp.relation.referenceQiu GF, 1999, ONCOGENE, V18, P623, DOI 10.1038/sj.onc.1202344
hcfmusp.relation.referenceSakthianandeswaren A, 2011, CANCER RES, V71, P3709, DOI 10.1158/0008-5472.CAN-10-2342
hcfmusp.relation.referenceSaude M, 2011, ESTIMATIVA 2012 INCI
hcfmusp.relation.referenceSchoelch ML, 1999, ORAL ONCOL, V35, P77, DOI 10.1016/S1368-8375(98)00065-7
hcfmusp.relation.referenceSellheyer K, 2011, J CUTAN PATHOL, V38, P542, DOI 10.1111/j.1600-0560.2011.01693.x
hcfmusp.relation.referenceSellheyer K, 2011, J CUTAN PATHOL, V38, P460, DOI 10.1111/j.1600-0560.2010.01671.x
hcfmusp.relation.referenceSharma AK, 2011, CLIN CANCER RES, V17, P4474, DOI 10.1158/1078-0432.CCR-10-2370
hcfmusp.relation.referenceShrestha-Bhattarai T, 2010, ONCOGENE, V29, P3873, DOI 10.1038/onc.2010.141
hcfmusp.relation.referenceSiegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
hcfmusp.relation.referenceToyoshima Y, 2004, J BIOL CHEM, V279, P25898, DOI 10.1074/jbc.M400661200
hcfmusp.relation.referenceZhao YM, 2008, CANCER BIOL THER, V7, P1867, DOI 10.4161/cbt.7.12.6945
hcfmusp.remissive.sponsorshipFAPESP
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication2640d453-a3aa-4d29-bb24-9a547c6c8712
relation.isAuthorOfPublication.latestForDiscovery2640d453-a3aa-4d29-bb24-9a547c6c8712
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_NAGAI_Expression_of_PAR_4_and_PHLDA1_is_prognostic_2013.PDF
Tamanho:
390.43 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03